Pulmonary Hypertension in Intensive Care Units: An Updated Review

Armin Nowroozpoor 1, Majid Malekmohammad 2, Seyyed Reza Seyyedi 3, Seyed Mohammadreza Hashemian 1

1 Clinical Tuberculosis and Epidemiology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2 Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran, 3 Lung Transplantation Research Center, Department of Cardiology, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence to: Hashemian SMR
Address: Clinical Tuberculosis and Epidemiology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Email address: iran.criticalcare@yahoo.com

INTRODUCTION

Pulmonary hypertension (PH) is a group of disorders, characterized by increased pulmonary artery pressure (PAP) exceeding the physiological level. The mean PAP (mPAP) ≥25 mmHg, measured by right heart catheterization (RHC) at rest, has been used for the diagnosis of PH (1). PH is classified into five main groups according to similarities in clinical presentations, pathological findings, hemodynamic features, and management strategies. Updated classifications by the Fifth World Symposium on Pulmonary Hypertension are outlined in Table 1 (2). Patients with PH are admitted to the intensive care unit (ICU) for a variety of reasons (Table 2). ICU admission due to undiagnosed group 1 PH or pulmonary arterial hypertension (PAH) has decreased substantially as a result of improved knowledge about the disease (3). The majority of these patients are treated with PAH-specific drugs before ICU admission (4, 5). There are seven approved pharmacological agents targeting three major molecular pathways for the treatment of PAH (6), with newer drugs under development. Despite advances in management strategies and emergence of specific pharmacotherapies, PAH remains a challenging disease with high mortality.
Survival of different PH groups (Table 1) and subgroups varies significantly (7, 8). Therefore, special attention must be paid to different mechanisms involved in the disease process. A retrospective cohort study by Saydain et al. on PH patients admitted to ICUs showed that severe PH, defined by right atrial pressure >20 mmHg, mPAP >55 mmHg, or cardiac index (CI) <2 L/min/m², was a significant independent predictor of mortality. However, factors including an underlying disease, sepsis, or presence of comorbidities alone were not found to be predictors of mortality (5).

Table 1. Causes of Pulmonary Hypertension in the Intensive Care Unit

| Cardiothoracic surgery | Deteriorating existing pulmonary hypertension | Acute on chronic pulmonary hypertension |
|------------------------|---------------------------------------------|----------------------------------------|
| Heart/Lung transplantation | Impaired medication use | Impaired medication use |
| Mitral valve surgery | Sepsis | Sepsis |
| Coronary artery bypass graft | Pneumonia | Pneumonia |
| Ventricular assist device placement | Acute on chronic pulmonary hypertension | Acute on chronic pulmonary hypertension |
| Pneumonectomy | Arrhythmias (esp. atrial fibrillation) | Arrhythmias (esp. atrial fibrillation) |

Table 2. Classification of pulmonary hypertension (updated from Simonneau et al. (2))

1. Pulmonary arterial hypertension
   1.1 Idiopathic PAH
   1.2 Heritable PAH
   1.2.1 BMPR2
   1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3
   1.2.3 Unknown
   1.3 Drug and toxin induced
   1.4 Associated with:
      1.4.1 Connective tissue disease
      1.4.2 HIV infection
      1.4.3 Portal hypertension
      1.4.4 Congenital heart diseases
      1.4.5 Schistosomiasis
1'. Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
1''. Persistent pulmonary hypertension of the newborn (PPHN)

2. Pulmonary hypertension due to left heart disease
   2.1 Left ventricular systolic dysfunction
   2.2 Left ventricular diastolic dysfunction
   2.3 Valvular disease
   2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies

3. Pulmonary hypertension due to lung diseases and/or hypoxia
   3.1 Chronic obstructive pulmonary disease
   3.2 Interstitial lung disease
   3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
   3.4 Sleep-disordered breathing
   3.5 Alveolar hypoventilation disorders
   3.6 Chronic exposure to high altitude
   3.7 Developmental lung diseases

4. Chronic thromboembolic pulmonary hypertension (CTEPH)

5. Pulmonary hypertension with unclear multifactorial mechanisms
   5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
   5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
   5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
   5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH

BMPR = bone morphogenic protein receptor type II; CAV1 = caveolin-1; ENG = endoglin; HIV = human immunodeficiency virus; PAH = pulmonary arterial hypertension.
Despite significant advances in the knowledge of PH, there are still controversies about PH with RV dysfunction, especially in terms of management. Intensive care management of PH mainly relies on expert opinion, and there is a scarcity of high-quality randomized clinical trials (RCTs). In this review, we first briefly described the pathophysiology of RV dysfunction in PH patients and then focused on the diagnostic approaches and management strategies based on the available literature. It should be noted that PH in pediatric patients was not examined.

**Pathophysiology of right ventricle dysfunction in pulmonary hypertension**

Although different groups of PH vary in terms of pathogenesis, there are still some similarities. Pathogenesis of PH includes three main pathways: 1) increased production of endothelins; 2) decreased production of prostacyclins; and 3) decreased production of nitric oxide (NO). Endothelin-1, as a potent vasoconstrictor, increases in patients with PH. This has been well established both in animal and human models of PH (10-14). However, it is not clear if it plays a causal role in the disease or is a consequence of it (6, 15-17). Endothelin-1 also increases smooth muscle cell proliferation and has mitogenic effects (18, 19).

Prostacyclin is a potent vasodilator, which acts by increasing the level of cyclic adenosine monophosphate. A decrease in the production of prostacyclin has been reported in patients with PAH. Prostacyclin also reduces vascular remodeling, inflammation, platelet aggregation, and thrombosis. Thromboxane, a potent vasoconstrictor, increases due to PAH, and an imbalance in prostacyclin/thromboxane production is a proposed mechanism in the development of PAH (19-24). NO, which is produced by endothelial cells, acts by increasing cyclic guanosine monophosphate (cGMP) to cause vasodilation. Decreased production of NP due to endothelial dysfunction has been shown to play a role in PH (25-27). Treatment of PH, especially PAH as the most studied variant of PH, focuses on different targets of these three major pathways. Currently, there are nine drugs in four classes, approved for the treatment of PAH. These classes include prostanoids, soluble guanylate cyclase stimulators, endothelin receptor antagonists (ERAs), and phosphodiesterase type 5 (PDE5) inhibitors (6, 28).

Normal pulmonary circulation is a so-called “high-flow, low-pressure” system. Its maintenance requires the reduction of pulmonary vascular resistance (PVR) in response to increased blood flow. Disruption in the normal vasodilatory reserve of pulmonary vessels and pulmonary vascular dysfunction are known to interrupt this system. The relationship between pressure, flow, and resistance is understandable based on the following equation:

\[ PVR = \left(\frac{mPAP - PCWP}{CO}\right) \times 80 \]

where PVR represents the pulmonary vascular resistance, mPAP is the mean pulmonary artery pressure, PCWP is the pulmonary capillary wedge pressure, and CO is the cardiac output. Due to the great potential of pulmonary vessels in vasodilation (ability of PVR to decrease significantly), an increased flow (measured as CO in the equation) does not lead to a considerable increase in PAP in physiological conditions. However, when this potential is compromised, the increased flow causes PAP to rise.

As described earlier, there are multiple etiologies for PH, but RV dysfunction and ultimately RV failure are common in severely ill patients. It is well established that RV function is an important predictor of survival in patients with PH (7, 9). As a result, RV failure should be emphasized in the treatment of patients with PH in ICUs. Most studies on ventricular failure are restricted to the LV. However, some findings can be also true for the right ventricle (RV). The RV, compared to the LV, has a thinner wall and a more complex geometry. From the front view, it is somewhat triangular (compared to the conical LV), and from the cross-sectional view, it is crescent-shaped. It has a convex free wall and a concave interventricular septum (29-31). Based on the Laplace’s law (see below), wall stress in a spherical or cylindrical chamber is directly
proportionate to the internal radius of the chamber and intraluminal pressure and inversely proportionate to the wall thickness: \( \sigma \propto \frac{P_r}{h} \).

where \( \sigma \) represents the wall tension, \( P \) denotes the RV pressure, \( r \) represents the internal radius of RV, and \( h \) is the wall thickness of RV. According to this equation, wall tension increases by increasing the intraluminal pressure. To prevent an excessive increase in wall tension, either the internal radius of RV should decrease or wall thickness of RV should increase. Wall tension is a good correlate of RV afterload. RV, due to its thin wall and low volume/surface area, shows greater compliance than the muscular thick-walled LV (LV).

Due to the increased RV afterload in PH, the RV wall hypertrophies as a physiological response to reduced wall tension. This process is considered a compensatory mechanism to oppose the increased wall tension (i.e., to decrease the RV wall tension). These adaptive mechanisms, however, cannot compensate for the sustained RV pressure overload, and the contractile force of RV does not suffice, leading to RV dilation and RV dysfunction. Increased RV mass also leads to increased myocardial oxygen demand (29, 32-34) (Figure 1).

LV is affected by RV due to ventricular interdependence. In other words, the anatomical and functional characteristics of one ventricle can affect the anatomical and functional characteristics of another (35-38). RV dysfunction causes an increase in the RV end-diastolic volume (RVEDV), which causes the interventricular septum to shift towards the LV. It also increases the pericardial constraint of LV during diastole. These changes decrease the LV end-diastolic volume (37, 38). Abnormal (paradoxical) septal motion may also impede LV ejection, reducing the LV flow during systole (37). This results in the diminished RV blood supply, which together with the increased oxygen demand of the hypertrophied RV (explained above), further deteriorates the oxygen supply/demand balance and leads to a more severe RV dysfunction (32, 37) (Figure 1).

**Figure 1.** Pathophysiologic cycle of right ventricle dysfunction in pulmonary hypertension. LV= left ventricle; LVEDV= left ventricle end-diastolic volume; RA= right atrium; RV= right ventricle; RVEDV= right ventricle end-diastolic volume; SV= stroke volume

**Evaluation of patients with pulmonary hypertension in Intensive Care Units**

**Clinical manifestations**

Most symptoms and signs of PH are non-specific, which causes a delay in diagnosis and initiation of treatment, especially in idiopathic PAH (39, 40). The symptoms may include dyspnea (especially on exertion), chest pain, coughs, palpitations, fatigue, orthopnea, paroxysmal nocturnal dyspnea, syncope, near-syncope, and peripheral edema. Abdominal pain, distension, and early satiety may also occur due to RV failure, causing hepatic congestion (41, 42). Moreover, hoarseness may occur with compression of the left recurrent laryngeal
nerve due to a dilated pulmonary artery (Ortner’s syndrome) (43). Hemoptysis rarely occurs, but if present, it is usually associated with PAH (44, 45) or concomitant pulmonary embolism, pulmonary infarction, or severe mitral stenosis (41).

Physical examination generally reveals signs of decompensated RV failure, including jugular vein distention, hepatomegaly, ascites, and peripheral pitting edema. Other signs may include a left parasternal lift, accentuated P2 sound, pansystolic murmurs due to tricuspid regurgitation, diastolic murmurs due to pulmonary insufficiency, S3 and S4 gallops, cooling of extremities, and diminished pulse pressure. Some signs may suggest a specific cause of PH; for example, the presence of venous stasis ulcers may suggest sickle cell disease (6, 46, 47).

Diagnostic tools and monitoring of pulmonary hypertension in intensive care units

Several tools may be used to improve the evaluation of patients with PH, including electrocardiography (ECG), echocardiography, chest X-ray, computed tomography (CT), RHC, and more recently, cardiac magnetic resonance (CMR) imaging and positron emitting tomography (PET). Moreover, laboratory markers may be helpful in identifying the specific causes of PH, monitoring of treatment, and patient prognosis.

ECG analysis

ECG remains an essential part of PH assessment. However, it is neither a specific nor a sensitive screening/diagnostic tool for PH. The RV strain has been shown to have more sensitivity for this purpose (48). A synthesized right-sided ECG seems to be more accurate in detecting PH; however, use of this type of ECG is less common (49). Positive findings are more likely to be found in severe PH and may include right axis deviation, RV hypertrophy, RV strain, P pulmonale, right bundle branch block, increased QTc interval, and QRS prolongation (6). Supraventricular tachyarrhythmias (SVTs) are the main dysrythmias in PH. Atrial flutter, atrial fibrillation, and AV-nodal reentrant tachycardia are the most common types. These conditions have a poor prognosis and further deteriorate the already impaired CO, leading to a rapid clinical decline (6, 50-52).

Chest X-ray

Chest X-ray is not a very suitable tool for the diagnosis of PH in the ICU setting, but it may reveal signs correlated with the disease severity or underlying factors. Signs, such as pulmonary arterial enlargement, RV hypertrophy, and an obscure aortopulmonary window, may not be observable on a portable image. Other signs which may help establish an underlying cause include pleural effusion and septal Kerley B lines (suggesting left heart disease), flat diaphragms and hyperinflated lungs (suggesting chronic obstructive pulmonary disease), and spine and chest wall abnormalities (suggesting restrictive pulmonary disease) (46, 53).

Echocardiography

Transthoracic echocardiography (TTE) with the use of Doppler ultrasound is the most available and widely used tool for diagnosing and monitoring patients with PH. Although it may not be an accurate tool, especially in critically ill patients, it provides valuable information for clinicians. It can effectively identify congenital heart diseases, such as intracardiac shunts or left heart disease as the underlying cause of PH (54). Moreover, it can estimate the right atrial pressure (RAP), mPAP, and level of RV dysfunction and help determine the underlying cause of PH non-invasively (55).

To estimate mPAP, TTE uses functional tricuspid regurgitation (TR), which occurs as a result of disturbance in the geometrical structure of RV in PH; therefore, this measurement is prone to over- or underestimation. Furthermore, an increase or decrease in mPAP is not necessarily correlated with the clinical status or prognosis of patients (6). Signs indicating a dysfunctional RV include RV and RA hypertrophies, dyskinesia of the right free wall of RV (McConnell’s sign), straightening or leftward bowing of the interventricular septum (D-shaped LV),
paradoxical movement of the septum in the systole, and a dilated inferior vena cava (53, 56, 57).

Evaluation of the RV size and function may be challenging due to its crescent shape and thin walls. Several parameters have been used to assess the RV function, which seem to be well correlated with the disease prognosis, including estimated RAP, RV longitudinal strain, tricuspid annular plane systolic excursion, right ventricular Tei index (myocardial performance index), RV fractional area change, and RV strain based on speckle tracking (6, 58-65). Other parameters that can be used at bedside to evaluate the RV function may include the RV/LV area ratio, LV eccentricity index, peak velocity of systolic excursion, and RV systolic pressure (66).

Three-dimensional (3D) echocardiography is emerging as a useful tool for the assessment of RV. It can accurately estimate the RV size and ejection fraction (EF) and improve the assessment of RV function non-invasively (67). The findings of 3D echocardiography are well correlated with cardiac MRI, and therefore, it is reasonable to use it as a non-invasive and accurate tool for the evaluation of RV function in combination with 2D echocardiography (68-70).

**Computed tomography scan**

Non-contrast CT scan is a readily available tool, which provides useful information about mediastinal structures, such as heart chambers, larger vessels, lung parenchyma, and bony structures. It can depict signs on the chest X-ray more accurately and help with the diagnosis of PH and its underlying causes. High-resolution CT may be especially helpful in evaluating the lung parenchyma and detecting interstitial lung disease, pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis. This modality is now recommended for all patients with PH (6, 71).

CT pulmonary angiography (CTPA) is a valuable tool in detecting arteriovenous malformations, pulmonary embolism, and CTEPH, with a specificity as high as 99% (72). Several indices have been proposed for diagnosing PH and assessing the disease severity, such as main pulmonary artery diameter and pulmonary artery-to-aorta ratio (73, 74). ECG-gated CTPA is associated with fewer motion-related artifacts and allows for the assessment of coronary arteries simultaneously (75, 76). The newer “dual-energy CT” has also shown comparable accuracy in detecting CTEPH and may help decide about the efficacy of CTEPH (75, 77, 78). However, conventional pulmonary angiography remains the gold standard for diagnosing patients who are suitable candidates for surgical interventions (i.e., pulmonary endarterectomy or balloon pulmonary angioplasty) (6).

**Ventilation/perfusion scintigraphy**

Ventilation/perfusion scintigraphy (V/Q scan) is the most sensitive screening tool of choice for detecting pulmonary embolism and CTEPH. A normal or a very-low-probability V/Q scan essentially rules out CTEPH. CTPA is more specific, but less sensitive than V/Q scans (6, 72). However, some studies have shown that CTPA is as sensitive and accurate as V/Q scan in detecting CTEPH (79). Definite diagnosis of CTEPH should be made through CTPA, conventional contrast angiography, or MR angiography (6).

**MRI studies**

Cardiovascular magnetic resonance (CMR) imaging is an accurate and reliable modality and the gold standard for the non-invasive assessment of RV size, geometry, and function (80); however, its use in the ICU setting is limited. It has been shown that estimation of mPAP, based on the ventricular mass index, is well correlated with RHC measurements (81). Nevertheless, it is not as accurate as RHC, and it is only used for monitoring patients and treatment response. By the measurement of the RV stroke volume (SV) and RV volume, CMR can detect RV dysfunction before it is clinically evident (80). Increased RV volume, decreased RV-SV and RV end-diastolic index (RVEDVI), and reduced LV volume seem to be associated with treatment failure and mortality (82, 83).

Magnetic resonance angiography (MRA) is used to differentiate idiopathic pulmonary arterial hypertension (IPAH) and CTEPH (84). MRA may be also helpful in diagnosing congenital heart disease if Doppler echocardiography is inconclusive. In addition, it can be
used as an alternative to CT angiography in case of iodine contrast contraindication (85). Moreover, hybrid PET-MRI is a novel technique, which allows for both structural and functional assessments of heart chambers and may shed more light on the pathophysiology of RV dysfunction. Furthermore, it may play multiple roles in the assessment of RV in patients with PH in the future (86).

**Right heart catheterization**

RHC is still considered the gold standard for the definite diagnosis of PH and analysis of vasoreactivity in patients with IPAH, heritable pulmonary arterial hypertension (HPAH), or drug-induced PAH, which may benefit from calcium channel blockers (6). However, application of RHC in the critical care setting has been debated. Many observational studies have found no improvement in the clinical outcomes of patients undergoing RHC for monitoring. RHC has been even associated with increased mortality and resource utilization (87, 88). Some RCTs comparing the management of critically ill patients with or without RHC found no significant difference regarding its benefits or harms (89-92). Moreover, a recent Cochrane meta-analysis comparing the same outcomes concluded the same results (93).

Different assessment methods (e.g., Fick’s method and thermodilution method) of CO with RHC may provide different results. Serious complications include arrhythmias, pneumothorax, hematoma at the insertion site, systemic hypotension, infection, and air or clot embolism. However, if performed by skilled experts, the morbidity and mortality associated with this procedure are relatively low (1.1% for the overall rate of serious adverse outcomes and <0.1% for fatal complications) (94). Extra caution must be exercised when performing RHC in patients with IPAH, HPAH, and PAH (due to the use of anorexigens) and patients with arrhythmias, as they may be receiving oral anticoagulants.

Based on these findings, use of RHC as a routine monitoring technique in critically ill patients has declined over the years due to its high cost, infrequent but serious complications, need for high expertise, and emergence of newer technologies. However, many experts still advocate for the use of RHC in patients with PH and severe RV dysfunction in the critical care setting (4, 53). Therefore, it is reasonable to decide about RHC on a case-by-case basis with regard to the patient’s clinical condition, physician’s expertise, and technical availability.

**Other measures**

Routine hematology, biochemistry, and thyroid function tests are required for all patients. Serial creatinine measurement should be performed, especially if the patient’s condition is deteriorating. Renal function is associated with increased mortality (95). Serological tests are required to diagnose the underlying cause of PH if previously undetermined. Arterial blood gas should be obtained to assess the partial pressure of oxygen (PaO₂) and partial pressure of carbon dioxide (PaCO₂) to guide management. Lung diffusion capacity for carbon monoxide is decreased in pulmonary veno-occlusive disease, scleroderma, and interstitial lung disease (6). Monitoring of coagulation status is essential, especially in those receiving anticoagulation therapy.

Many biochemical markers have been studied for the detection, prognosis, and treatment response of patients with PH. Brain natriuretic peptide (BNP), a cardiac hormone, and N-terminal pro-brain natriuretic peptide (NT-proBNP), its inactive alternative, are the most important studied markers. Both BNP and NT-proBNP are elevated as a result of increased ventricular wall tension. They are recognized as markers of dysfunction in both ventricles; therefore, they are not specific to RV (96, 97). BNP/NT-proBNP is correlated with mPAP (98). Moreover, the level of NT-proBNP during treatment is correlated with RVEDVI, RV mass index, RV-EF (99), and PVR (100). The prognostic values of both BNP and NT-proBNP are well established (101-104). Changes in the level of these markers represent the treatment response and can guide
management although they are not suitable tools for diagnosing RV dysfunction.

Management

Management of PH patients with RV dysfunction and decompensated RV failure has not been studied exclusively in critical care settings, and there is no standard guideline. In this section, we mainly focus on managing RV dysfunction caused by PH in critical care settings. General management strategies for PH are provided in detail by the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines (6). According to the Frank-Starling law, SV of a ventricle is dependent on three factors: 1) preload, 2) afterload, and 3) inotropy (contractility). With a constant afterload and inotropy, SV is determined by preload.

Dilation leads to increased sarcomere length in physiological limits, resulting in increased contractile force. In a chronically volume-overloaded RV, SV is relatively preserved with hypertrophy of RV. However, with further volume overload or acute volume/pressure overload of the RV (e.g., acute pulmonary embolism), RV fails to maintain a normal SV. This is primarily due to the increased length of sarcomeres beyond their physiological limit, which results in decreased contractility (36). In this section, management strategies will be discussed in three main categories: optimization of 1) RV preload, 2) RV afterload, and 3) RV contractility (36, 105). Instead of a step-wise approach, all three categories must be considered simultaneously as they are intricately related.

Right ventricle preload

Assessment of the patient’s volume status is a very important and challenging issue, especially in critical care. The ultimate goal of physicians is to provide adequate and effective intravascular volume. This is necessary for effective perfusion of both systemic and pulmonary circulations. Fluid therapy is a controversial topic in the management of RV failure. It is difficult to define the optimal goal of RV preload in patients with RV failure, and it is somewhat unknown whether increasing the RV preload has beneficial effects in a failing RV.

RAP, RVEDV, and RVEDP are usually considered as surrogates for the RV preload (30). In a 1999 study on patients with acute massive pulmonary embolism and normal systemic pressure, fluid loading was shown to increase RAP, RVEDVI, stroke volume index, and CI; however, it did not affect EF or PVR (106). An excess increase in preload causes more ventricular dilation, resulting in increased wall stress, ischemia, and leftward interventricular septal shift (see pathophysiology above) and deterioration of RV and LV function (Figure 1).

Many experts advocate for modest fluid loading in patients suspected of having a low preload (36, 107, 108). It should be performed with initial assessment and continuous monitoring, such as using a central venous line; however, it should not continue if clinical improvement does not occur (36, 109). With a central venous pressure (CVP) ≥12-15 mmHg, fluid loading should be withheld, and measures should be taken to decrease the afterload and increase the inotropy (108).

Two measures that can improve the assessment of fluid responsiveness include passive leg raising (PLR) and respiratory variations in thoracic pressure. PLR is essentially useful in patients who are neither on vasoconstrictors nor mechanically ventilated. A positive PLR suggests that the patient will respond to fluid loading (110-112). Changes in pulse pressure in mechanically ventilated patients can predict fluid responsiveness. However, this technique cannot be used in patients with dysrhythmias or tachycardia (110).

Most cases of RV failure involve volume overload and require diuretics or hemodialysis to remove the excess fluid (4, 109). The amount of fluid needed to be removed may be substantial for significant improvement of RV function (105). An optimal RV filling pressure of 8-12 mmHg has been suggested by some authors (105, 109). Achieving a normal superior vena cava O₂ saturation of 70-80% can be also used to guide the amount of fluid removal, as it is a marker of CO (105). Regarding diuretics, a loop diuretic, such as furosemide, is usually used to remove the
excess fluid. A continuous infusion is preferred, as it is titratable to achieve optimal filling pressures. If response to high-dose loop diuretics is not favorable, a thiazide diuretic can be added (107). If the diuretic response is still inadequate, the patient may undergo hemodialysis or ultrafiltration. Echocardiography may also guide the management of fluids, either fluid loading or removal, by comparing the indices of RV function before and after therapy (66) (see echocardiography above).

**Right ventricle afterload**

Increased RV afterload is an important component of PH and RV failure. Pulmonary vasodilators and PAH-specific pharmacotherapy play major roles in managing these patients since RV is especially vulnerable to increased afterload. Prostacyclins, inhaled NO, ERAs, and PDE5Is are the available options, although there is a scarcity of high-quality RCTs on the management of these patients in critical care settings. PAH-specific drugs should be used with caution in PH groups other than PAH, as they may not be effective and may have potential complications (107, 113, 114). PAH-specific drugs may be beneficial in inoperable CTEPH and perioperative PH (6, 115, 116). It should be noted that many previously diagnosed PAH patients may be already receiving a combination of PAH-specific drugs, which is an increasingly common practice.

**Prostacyclins**

Prostacyclins are the mainstay treatment for PAH and severe PH with RV dysfunction. Their effects may be the greatest in patients without previous prostacyclin treatment and those with a more severe disease. Intravascular infusion of epoprostenol or treprostinil is usually used as the initial treatment (117). Dosing starts at 1-2 ng/kg/min and then increases by 1-2 ng/kg/min every 15-30 minutes for epoprostenol and by 5 ng/kg/min for treprostinil. Dosing increases gradually until a favorable hemodynamic response or maximum patient tolerability is achieved. Epoprostenol, due to its shorter half-life (3-6 minutes) than treprostinil (2-4 hours), may be theoretically a better option in critical care settings. Treprostinil can be also administered as a subcutaneous infusion with the same dosage and similar effects, although pain at the site of infusion may be a major setback (118-122). Patients receiving subcutaneous treprostinil may be transitioned to intravenous epoprostenol (preferred) or intravenous treprostinil, with dose adjustments in the ICU (123, 124).

Attention must be paid to potential systemic vasodilation and hypotension with systemic prostacyclins. Inhaled prostacyclins are less potent in inducing systemic hypertension. Since they are only delivered to ventilated alveoli, they can theoretically reduce the V/Q mismatch (105). Inhaled epoprostenol, which has been used in a few studies, increases the CI and mixed venous oxygen saturation and reduces mPAP and CVP, without decreasing the systemic arterial pressure (115, 116, 125). Also, some limited studies have shown the favorable outcomes of inhaled epoprostenol in acute respiratory distress syndrome (ARDS) and perioperative PH and RV failure (115, 126-130).

Inhaled treprostinil, starting at 18 mcg four times a day, improved the quality of life and NT-proBNP in a 12-week double-blind RCT on PAH patients already on sildenafil or bosentan (131). In a previous study, the combined use of inhaled treprostinil and sildenafil in patients with PAH and CTEPH caused a significant reduction in PVR and mPAP and increased CO (132). Other studies have also shown the favorable hemodynamic effects and minor side effects of inhaled treprostinil in PH patients (133-138). It is known that inhaled iloprost decreases PVR, mPAP, mean arterial pressure (MAP), and PaO₂ in patients with CTEPH (139). Long-term inhaled iloprost at 2.5-5 mcg (6-9 times per day) has been also used to treat severe PH (140). It has been also administered in patients undergoing cardiothoracic surgery, mitral valve surgery, and cardiopulmonary bypass (115, 141, 142).
Selexipag is a novel selective prostacyclin receptor agonist, approved for the treatment of PAH (143). When used in combination with ERAs and/or PDE5Is, it can reduce PVR and mPAP and increase CO and CI; however, it has not been shown to reduce mortality (144, 145). Use of selexipag in critically ill patients has not been studied, and it should not be initiated in a critical care setting if the patient is not already receiving it.

**Nitric oxide (NO)**

Inhaled NO (iNO) has become a routine part of the management of patients with ARDS and many patients with PH and RV failure. Similar to inhaled prostacyclins, iNO exerts its effects on well-ventilated areas of the lung and improves the V/Q mismatch (146). It is known that iNO undergoes rapid metabolism by hemoglobin in the pulmonary system, and its very short half-life requires continuous administration. Risk of methemoglobinemia, albeit low, increases by increasing the dose and prolonging the use (147). It has been shown that iNO reduces mPAP and PVR, increases the RV-EF, and improves oxygenation in patients with ARDS and PH; however, these outcomes are mostly transient. In this regard, a recent meta-analysis showed that iNO does not result in reduced mortality or decreased length of hospital/ICU stay and may even increase the risk of renal failure (148).

Despite the fact that all prostacyclins can improve the hemodynamic parameters, only epoprostenol seems to reduce long-term mortality in patients with idiopathic PAH (121, 149, 150). In a previous study, inhaled epoprostenol and iNO resulted in similar reductions in mPAP among patients with PH undergoing thoracic surgery. Both groups had a similar duration of mechanical ventilation, hospital stay, ICU stay, and in-hospital mortality, although the cost of inhaled epoprostenol was significantly lower than iNO (151). Both iNO and prostacyclins should not be discontinued abruptly, as they may cause rebound PH and RV failure (152, 153).

**Phosphodiesterase 5 inhibitors (PDE5Is)**

PDE5Is increase the cGMP level, cause vasodilation, and reduce smooth muscle cell proliferation, mPAP, and PVR (154, 155). Sildenafil and tadalafil are FDA-approved drugs for the treatment of PAH, which cause vasodilation; their peak effects are seen 60 and 75-90 minutes after administration, respectively (156). They both exhibit selectivity for pulmonary vasculature although systemic hypotension may occur (156). Only sildenafil has been shown to increase arterial oxygenation (156).

Sildenafil with iNO exerts synergistic hemodynamic effects and prevents rebound PH seen in iNO withdrawal (157-162). Sildenafil has been used preoperatively in patients with severe PH undergoing surgery. Sildenafil has been also used in combination with prostacyclins and ERAs, causing greater improvements in the hemodynamics (132, 163-169). Oral sildenafil has a rapid onset (15-30 minutes) and a short duration of action (4-6 hours). It is suitable for use in ICUs (107), although its intravenous form is also available (170-172).

**Right ventricle contractility**

In a failing RV, improvement of contractility should be considered. Drugs used to decrease the RV afterload, such as intravenous prostacyclins, can also increase the RV contractility (173). Studies comparing different inotrope and vasopressor agents, especially in PH patients, are scarce. Milrinone, as an inodilator, is a phosphodiesterase-3 (PDE-3) inhibitor, which increases cAMP, leading to vasodilation and increased contractility (174-176). In addition, it can improve oxygenation, decrease PVR, and increase RV-SV (176, 177). Milrinone can cause systemic hypotension and increase the need for vasopressors. However, removal of the bolus dose before infusion may prevent these outcomes (178-180).

Intravenous administration of milrinone in combination with iNO has shown greater effectiveness than their administration alone (181, 182). Inhaled milrinone may be used to avoid adverse effects, such as systemic hypotension (183-185). In a study of PH following cardiac surgery, inhaled milrinone in combination with inhaled epoprostenol could decrease mPAP and PVR and increase RV-SV (186). Therefore, intravenous milrinone should be used with caution and preferentially as the last
resort. Milrinone can also help prevent rebound hypertension due to iNO withdrawal by preserving the cAMP levels (187).

Although dopamine increases CI, it can cause tachycardia and increase the PVR/SVR ratio (36). Its effects may come at the cost of increased arrhythmic events and mortality in patients with cardiogenic shock (36, 188, 189). Dobutamine improves hemodynamics in patients with PH undergoing liver transplantation. It also improves RV infarction-induced PH, as well as PH in heart failure patients with preserved EF (190-192). In a previous study, administration of low-dose dopamine and/or dobutamine (starting at 3 mcg/kg/min) at the onset of epoprostenol treatment was a safe option in PAH patients and did not increase mPAP (193). At doses higher than 5 mcg/kg/min, dobutamine may cause systemic hypotension and require the use of a vasopressor, such as norepinephrine (53). Dobutamine (10 mcg/kg/min) in combination with iNO can increase CI and PaO\textsubscript{2} and decrease PVR and SVR, without changing the mPAP or MAP (194). Therefore, many clinicians prefer using dobutamine over dopamine (6, 107).

Levosimendan is a calcium sensitizer, which increases myocardial contractility unlike β-adrenergic agonists and PDE-3 inhibitors, without increasing the intracellular calcium. It also causes pulmonary and coronary vasodilation (195, 196). It has the advantage of not increasing myocardial O\textsubscript{2} consumption and even decreasing it (195). In animal models of PH, levosimendan has been shown to increase the RV contractility, SV, CI, and RV-PA coupling, while decreasing PVR (197-199). Levosimendan may be associated with an increased need for norepinephrine infusion (200, 201). Studies on the effects of levosimendan on mortality have yielded inconclusive results (202). Short-term use of levosimendan in patients with PH and RV failure, especially in case of biventricular failure, may be considered (36). Epinephrine increased SV, CI, and MAP, but did not increase PVR in animal models of acute PH (203-205). In a small pilot open-label clinical trial on pediatric patients with PH, epinephrine increased the aortic pressure and mPAP and exerted inconsistent effects on the PVR/SVR ratio in different patients (206).

**Vasopressors**

In addition to dopamine and epinephrine, other vasopressors include norepinephrine, phenylephrine, and arginine vasopressin. In case of systemic hypotension, use of a suitable vasopressor is required. Furthermore, maintaining the aortic root pressure is vital for adequate coronary perfusion in both RV and LV. The ideal vasopressor is one that increases SVR to maintain MAP, without increasing PVR, which results in an unfavorable increase in mPAP.

Norepinephrine exerts its effect through α-1 and β-1 stimulation (207). It causes systemic and pulmonary vasoconstriction through α-1 stimulation, thereby increasing SVR and PVR (208). However, as shown in animal studies and one human case report, low doses of norepinephrine are usually used in clinical settings (<0.5 mcg/kg/min), and an increase in PVR is less likely (209, 210). Due to its inotropic effects, norepinephrine increases the RV contractility, RV-PA coupling, and CO (209, 211-213). In chronic PH and RVF, norepinephrine decreases the PVR/SVR ratio in patients with normal CI (214).

Phenylephrine at low doses only activates α-1 receptors and does not have β sympathetic activity (207). In patients with chronic PH, it increases SVRI, PVRI, MAP, and mPAP, but it does not change mPAP/MAP or PVRI/SVRI ratio. At higher doses, phenylephrine decreases CI, compared to norepinephrine. Although phenylephrine may improve the coronary blood flow, it may have deleterious effects on the RV function and CO (204, 212, 215); therefore, its use is usually limited.

Arginine vasopressin (AVP) is a potent vasopressor, exerting its effects through V1 receptors on vascular smooth muscle cells (207). AVP causes systemic vasoconstriction, while at low doses, it causes selective pulmonary vasodilation, resulting in decreased or preserved PVR and PVR/SVR ratio (216-221). However, there is conflicting information regarding its pulmonary
vasodilatory role and effects on RV function (219, 222, 223); also, at higher doses, it seems to produce pulmonary vasoconstriction (224). Additionally, AVP may have age-dependent effects, as it does not cause pulmonary vasodilation in neonate rats (225). AVP may be useful in decreasing the required dose for concurrent vasopressor use in patients with septic shock (219, 226-228), although no favorable effects on mortality have been reported (226). There are some case-reports on the clinical use of AVP in acute (229) and chronic PH (230-232). However, more studies are needed for a better understanding of its effect in this population.

Oxygenation and mechanical ventilation

Adequate oxygenation is of utmost importance in ICU patients with PH. Alveolar and arterial hypoxia, acidosis, and hypercapnia can all cause pulmonary vasoconstriction (36), which in turn may exacerbate these conditions; therefore, measures should be taken to end this cycle. Oxygen saturation should be kept at >90-92% (105, 233, 234). It should be noted that supplemental oxygen decreases the heart rate, mPAP, and CO (235). Both hyperinflation and atelectasis decrease the alveolar blood flow and increase PVR. The effects on PVR are minimal at functional residual capacity (36, 109). Increased intrathoracic pressure, which occurs with positive pressure ventilation, increases the RV afterload and decreases the RV-EF (236). Intubation should be avoided in cases of RV failure (6) for as long as possible, as it is associated with increased in-hospital mortality. In a large cohort study of patients with PAH, the in-hospital mortality was 39.1% in patients undergoing invasive mechanical ventilation versus 12.1% in those undergoing non-invasive mechanical ventilation (P<0.001). Overall, high-flow oxygen, administered through the nasal cannula, may be a safer option (237).

Many authors have discouraged permissive hypercapnia in patients with PH (4, 53, 107) as increased CO₂ levels may increase PVR and mPAP and deteriorate RV function due to pulmonary vasoconstriction (238, 239). This vasoconstriction may be reversed using iNO (240). In contrast, some animal studies have found a protective role for CO₂ in PH induced by chronic hypoxia (241, 242). It may be reasonable to consider PaCO₂ of 48-50 mmHg as the upper limit, as it is considered for patients with ARDS (243). Moderate hypercapnia (PaCO₂= 60-70 mmHg) may be tolerated in selected cases (244).

Other lung-protective ventilation strategies for ARDS, which may be reasonable in patients with PH and RV failure, include lower tidal volume (<6 ml/kg of ideal body weight), optimization of PEEP (≤10 cm H₂O if clinically feasible) (245), lower plateau pressure (<30 cm H₂O) (246, 247), and consequently lower driving pressure (248, 249). However, these decisions should be made on a case-by-case basis, as an individual’s response to different ventilation mechanisms varies (250). Newly emerging extracorporeal CO₂ removal devices may allow for the use of even lower tidal volumes (<4 ml/kg of ideal body weight) and PEEPs in the future (ultra-protective ventilation) (251).

Extracorporeal membrane oxygenation (ECMO) may be used either as a bridge to transplantation or as a bridge to recovery in decompensated PH and RV failure until other therapeutic measures are applied to manage the condition. Veno-arterial ECMO must be used rather than veno-venous ECMO as it can unload RV in addition to providing oxygenation (252). Application of ECMO, pre-, intra-, and post-lung transplant may have favorable effects on cardiac function and mortality and allow for earlier weaning from mechanical ventilation postoperatively (253, 254).

Left-, right- and bi-ventricular assist devices (LVADs, RVADs, and BiVADs) may be used in patients with severe ventricular dysfunction. A failing RV may help with the insertion of RVAD to improve the RV function. Improvement of RV function comes at the expense of increased PVR, PAP, and damage to the pulmonary microcirculation, leading to pulmonary hemorrhage; this is more prominent with pulsatile flow, compared to constant flow systems (255, 256). Increased duration (>7 days) and
flow of RVAD (>4 L/min) (257) are associated with increased mortality.

Many patients require RVAD insertion due to RV failure after LVAD placement or BiVAD placement due to biventricular failure (258-262). There are reports of isolated RVAD placement for RVF in patients with RV infarction, orthotopic heart transplant (263-268), and RVF with PH (269-274). Percutaneous RVADs are effective and do not require sternotomy (269, 275). A pumpless lung assist device acts as an artificial lung and may be used as a bridge to lung transplant in patients with PAH. It connects the pulmonary artery trunk to the left atrium, with blood passing through a membrane oxygenator. It can unload the RV by bypassing the high resistance pulmonary vasculature. Although it is effective in removing CO2, it does not provide significant or adequate oxygenation. Additionally, the blood flow exclusively relies on the pressure gradient from the pulmonary artery to the left atrium (276-278). In this regard, Vasanthan et al. reported a patient on a pumpless lung assist device for 82 days before undergoing heart and bilateral lung transplantation (279).

**Arrhythmias**

SVTs, including atrial flutter and atrial fibrillation, are the most prevalent arrhythmias in PAH, while ventricular arrhythmias are rare. SVTs are associated with impaired RV function, clinical deterioration, and increased mortality in case of atrial fibrillation, while restoring the sinus rhythm improves the RV function. Rhythm control is more important in PAH, while rate control is more important in non-PAH patients with LVF (52). Electric cardioversion and ablation therapy are both safe and effective in rhythm control. Sinus rhythm should be maintained using antiarrhythmic drugs, without any major negative inotropic activity (6). Bradycardia in PAH is alarming as it is highly associated with cardiopulmonary arrest (52). Oral anticoagulation should be initiated in all patients with SVTs (6).

**Other measures**

Graded balloon dilation atrial septostomy may be performed only in specialized centers as palliative care or a bridge to transplantation when medical therapies have failed (280, 281). It creates a right-to-left shunt, bypassing the lungs, unloading the RV, and increasing the LV preload and CO. Although oxygenation decreases, tissue oxygen delivery improves. This procedure should not be performed in patients with very severe PH with a mean baseline RAP >20 mmHg and O2 saturation <85% at rest in the room air (6). Stent fenestration of the septum may be performed to prevent the closure of the foramen (282). Intra-aortic balloon counterpulsation is used in case of severe heart failure to improve the LV function by decreasing the LV preload, afterload, and oxygen demand (283) and to increase the coronary blood flow if coronary autoregulation is impaired (283, 284). Use of this method has been reported in animal models of RV failure (285-287) following cardiopulmonary bypass (288, 289) and heart transplant (290, 291).

**CONCLUSION**

Management of PH in the ICU setting is challenging for clinicians. In patient care, the type of PH, its pathophysiology, underlying exacerbating factor, and individual patient characteristics must be taken into account since there is no clear understanding or consensus on many aspects of management. In addition, the exacerbating factor (e.g., infection and anemia) should be identified and treated promptly. Principal measures, such as optimizing the RV afterload, preload, and contractility, should be also addressed. PAH-specific therapies continue to evolve over time, with newer medications and findings changing the practice. Assessment of the volume status is critical, mandating fluid therapy and/or diuretics along with other measures. Moreover, RV contractility must be improved using appropriate drugs if the patient’s findings suggest RV failure. Pulmonary vasodilators are a promising option for decreasing the RV afterload. However, maintaining the systemic blood pressure with vasopressors is challenging as they eventually increase PAP. Palliative or bridging strategies, such as mechanical...
support, should be also considered in certain candidates. Future studies should address the uncertainties surrounding this rare, but fatal disease.

REFERENCES

1. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. *J Am Coll Cardiol* 2013;62(25 Suppl):D42-50.

2. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2013;62(25 Suppl):D34-41.

3. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. *Eur Respir J* 2011;38(2):359-67.

4. Hoeper MM, Granton J. Intensive care unit management of patients with severe pulmonary hypertension and right heart failure. *Am J Respir Crit Care Med* 2011;184(10):1114-24.

5. Saydain G, Awan A, Manickam P, Kleinow P, Badr S. Pulmonary Hypertension an Independent Risk Factor for Death in Intensive Care Unit: Correlation of Hemodynamic Factors with Mortality. *Clin Med Insights Circ Respir Pulm Med* 2015;9:27-33.

6. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Respir J* 2015;46(4):903-75.

7. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. *Ann Intern Med* 1991;115(5):343-9.

8. Hurdman J, Condliffe R, Elliot CA, Davies C, Hill C, Wild JM, et al. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. *Eur Respir J* 2012;39(4):945-55.

9. Sandoval J, Bauerle O, Palomar A, Gómez A, Martínez-Guerra ML, Beltrán M, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. *Circulation* 1994;89(4):1733-44.

10. Cacoub P, Dorent R, Nataf P, Carayon A, Riquet M, Noe E, et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. *Cardiovasc Res* 1997;33(1):196-200.

11. Cernacek P, Stewart DJ. Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. *Biochem Biophys Res Commun* 1989;161(2):562-7.

12. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. *N Engl J Med* 1993;328(24):1732-9.

13. Horgan MJ, Pinheiro JM, Malik AB. Mechanism of endothelin-1-induced pulmonary vasoconstriction. *Circ Res* 1991;69(1):157-64.

14. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. *Circulation* 1991;84(6):2280-5.

15. Biasin V, Chwalek K, Wilhelm J, Best J, Marsh LM, Ghanim B, et al. Endothelin-1 driven proliferation of pulmonary arterial smooth muscle cells is c-fos dependent. *Int J Biochem Cell Biol* 2014;54:137-48.

16. Goerre S, Wenk M, Bärtsch P, Lüscher TF, Niroomand F, Hohenhaus E, et al. Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. *Circulation* 1995;91(2):359-64.

17. Lambers C, Roth M, Zhong J, Campregger C, Binder P, Burian B, et al. The interaction of endothelin-1 and TGF-β1 mediates vascular cell remodeling. *PLoS One* 2013;8(8):e73399.

18. Hassoun PM, Thappa V, Landman MJ, Fanburg BL. Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. *Proc Soc Exp Biol Med* 1992;199(2):165-70.
19. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. *J Am Coll Cardiol* 2004;43(12 Suppl S):135-245.

20. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. *Circulation* 2004;109(2):159-65.

21. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. *N Engl J Med* 1992;327(2):70-5.

22. Mitchell JA, Ahmetaj-Shala B, Kirkby NS, Wright WR, Mackenzie LS, Reed DM, et al. Role of prostacyclin in pulmonary hypertension. *Glob Cardiol Sci Pract* 2014;2014(4):382-93.

23. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. *Am J Respir Crit Care Med* 1999;159(6):1925-32.

24. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. *Circulation* 1982;66(2):334-8.

25. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. *N Engl J Med* 1995;333(4):214-21.

26. Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2013;188(6):639-46.

27. Rubenfire M, Bayram M, Hector-Word Z. Pulmonary hypertension in the critical care setting: classification, pathophysiology, diagnosis, and management. *Crit Care Clin* 2007;23(4):801-34, vi-vii.

28. Humbert M, Ghofrani HA. The molecular targets of approved treatments for pulmonary arterial hypertension. *Thorax* 2016;71(1):73-83.

29. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. *Coron Artery Dis* 2005;16(1):13-8.

30. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. *Circulation* 2008;117(11):1436-48.

31. Ho SY, Nihoyannopoulos P. Anatomy, echocardiography, and normal right ventricular dimensions. *Heart* 2006;92 Suppl 1:2-13.

32. Poor HD, Ventetuolo CE. Pulmonary hypertension in the intensive care unit. *Prog Cardiovasc Dis* 2012;55(2):187-98.

33. Voelkel NF, Quaiife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. *Circulation* 2006;114(17):1883-91.

34. Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. *J Am Coll Cardiol* 2013;62(25 Suppl):D22-33.

35. Jardin F. Ventricular interdependence: how does it impact on hemodynamic evaluation in clinical practice?. *Intensive care medicine*. 2003;29(3):361-3.

36. Price LC, Wort SJ, Finney SJ, Marino PS, Brett SJ. Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. *Crit Care* 2010;14(5):R169.

37. Via G, Braschi A. Pathophysiology of severe pulmonary hypertension in the critically ill patient. *Minerva Anestesiol* 2004;70(4):233-7.

38. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. *Circulation* 2008;117(13):1717-31.

39. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brandung BH, Detre KM, et al. Primary pulmonary hypertension: A national prospective study. *Ann Intern Med* 1987;107(2):216-23.

40. Strange G, Gabbay E, Kermeen F, Williams T, Carrington M, Stewart S, et al. Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: The delay study. *Pulm Circ* 2013;3(1):89-94.

41. Rich JD, Rich S. Clinical diagnosis of pulmonary hypertension. *Circulation* 2014;130(20):1820-30.
42. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361(9368):1533-44.
43. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998;352(9129):719-25.
44. Almagro P, Julià J, Sanjaume M, González G, Casalots J, Heredia JL, et al. Pulmonary capillary hemangiomatosis associated with primary pulmonary hypertension: report of 2 new cases and review of 35 cases from the literature. Medicine (Baltimore) 2002;81(6):417-24.
45. Roofthooft MT, Douwes JM, Vrijlandt EJ, Berger RM. Frequency and prognostic significance of hemoptysis in pediatric pulmonary arterial hypertension. Am J Cardiol 2013;112(9):1505-9.
46. Barst RJ, McGoon M, Torbicki A, Sitbon O, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):40S-47S.
47. Lilly LS, Braunwald E. Braunwald’s heart disease: a textbook of cardiovascular medicine. Elsevier Health Sciences; 2012.
48. Bonderman D, Wexberg P, Martinzschin AM, Heinzl H, Lang MB, Sadushi R, et al. A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J 2004;33(12 Suppl 5):40S-47S.
49. Nakatsuji A, Miyauchi Y, Iwasaki YK, Tsuboi I, Hayashi H, Uetake S, et al. Detection and Evaluation of Pulmonary Hypertension by a Synthesized Right-Sided Chest Electrocardiogram. J Nippon Med Sch 2015;82(3):136-45.
50. Bandorski D, Schmitt J, Kurzlechner C, Erkapic D, Hamm CW, Seeger W, et al. Electrophysiological studies in patients with pulmonary hypertension: a retrospective investigation. Biomed Res Int 2014;2014:617565.
51. Greenwood JC, Spangler RM. Management of Crashing Patients with Pulmonary Hypertension. Emerg Med Clin North Am 2015;33(3):623-43.
52. Rajdev A, Garan H, Biviano A. Arrhythmias in pulmonary arterial hypertension. Prog Cardiovasc Dis 2012;55(2):180-6.
53. Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 2007;35(9):2037-50.
54. François CJ, Schiebler ML. Imaging of Pulmonary Hypertension. Radiol Clin North Am 2016;54(6):1133-1149.
55. Rudski LG, Lai WW, Afifalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23(7):685-713; quiz 786-8.
56. McConnell MV, Solomon SD, Rayan ME, Come PC, Goldhaber SZ, Lee RT. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol 1996;78(4):469-73.
57. Schiebler ML, Runo J, Jensen L, François CJ. Imaging of Pulmonary Hypertension. In: Kanne PJ, editor. Clinically Oriented Pulmonary Imaging. Totowa, NJ: Humana Press; 2012. p. 139-60.
58. Anavekar NS, Gerson D, Skali H, Kwong RY, Yucel EK, Solomon SD. Two-dimensional assessment of right ventricular function: an echocardiographic-MRI correlative study. Echocardiography 2007;24(5):452-6.
59. Austin C, Allassa K, Burger C, Safford R, Pagan R, Dueo L, et al. Echocardiographic assessment of estimated right atrial pressure and size predicts mortality in pulmonary arterial hypertension. Chest 2015;147(1):198-208.
60. Blanchard DG, Malouf PJ, Gurudevan SV, Auger WR, Madani MM, Thistlethwaite P, et al. Utility of right ventricular Tei index in the noninvasive evaluation of chronic thromboembolic pulmonary hypertension before and after pulmonary thromboendarterectomy. JACC Cardiovasc Imaging 2009;2(2):143-9.
61. D’Andrea A, Stanzoli A, D’Alto M, Di Palma E, Martino M, Scarafili R, et al. Right ventricular strain: An independent predictor of survival in idiopathic pulmonary fibrosis. Int J Cardiol 2016;222:908-910.
62. Fine NM, Chen L, Bastiansen PM, Frantz RP, Pellikka PA, Oh JK, et al. Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. Circ Cardiovasc Imaging 2013;6(5):711-21.
63. Ghio S, Pica S, Klersy C, Guzzafame E, Scelzi L, Raineri C, et al. Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy. *Open Heart* 2016;3(1):e000408.

64. Lu KJ, Chen JX, Profitis K, Kearney LG, DeSilva D, Smith G, et al. Right ventricular global longitudinal strain is an independent predictor of right ventricular function: a multimodality study of cardiac magnetic resonance imaging, real time three-dimensional echocardiography and speckle tracking echocardiography. *Echocardiography* 2015;32(6):966-74.

65. Sachdev A, Villarraga HR, Frantz RP, McGoon MD, Hsiao JF, Maalouf JF, et al. Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. *Chest* 2011;139(6):1299-1309.

66. Krishnan S, Schmidt GA. Acute right ventricular dysfunction: real-time management with echocardiography. *Chest* 2015;147(3):835-846.

67. Peluso D, Tona F, Muraru D, Romeo G, Cucchini U, Marra MP, et al. Right ventricular geometry and function in pulmonary hypertension: Non-invasive evaluation. *Diseases* 2014;2(3):274-95.

68. Bossone E, D’Andrea A, D’Alto M, Citro R, Argiento P, Ferrara F, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. *J Am Soc Echocardiogr* 2013;26(1):1-14.

69. Di Bello V, Conte L, Delle Donne MG, Giannini C, Barletta V, Fabiani I, et al. Advantages of real time three-dimensional echocardiography in the assessment of right ventricular volumes and function in patients with pulmonary hypertension compared with conventional two-dimensional echocardiography. *Echocardiography* 2013;30(7):820-8.

70. Vitarelli A, Mangieri E, Terzano C, Gaudio C, Salsano F, Rosato E, et al. Three-dimensional echocardiography and 2D-3D speckle-tracking imaging in chronic pulmonary hypertension: diagnostic accuracy in detecting hemodynamic signs of right ventricular (RV) failure. *J Am Heart Assoc* 2015;4(3):e001584.

71. Ley S, Kreitner KF, Fink C, Heussel CP, Borst MM, Kauczor HU. Assessment of pulmonary hypertension by CT and MR imaging. *Eur Radiol* 2004;14(3):359-68.

72. Tunariu N, Gibbs SJ, Win Z, Gin-Sing W, Graham A, Gishen P, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. *J Nucl Med* 2007;48(5):680-4.

73. Shen Y, Wan C, Tian P, Wu Y, Li X, Yang T, et al. CT-base pulmonary artery measurement in the detection of pulmonary hypertension: a meta-analysis and systematic review. *Medicine (Baltimore)* 2014;93(27):e256.

74. Tan RT, Kuzo R, Goodman LR, Siegel R, Haasler GB, Presberg KW. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Medical College of Wisconsin Lung Transplant Group. *Chest* 1998;113(5):1250-6.

75. Gopalan D, Blanchard D, Auger WR. Diagnostic Evaluation of Chronic Thromboembolic Pulmonary Hypertension. *Ann Am Thorac Soc* 2016;13 Suppl 3:S222-39.

76. Shuman WP, Leipsic JA, Busey JM, Green DE, Pipavath SN, Hague CJ, et al. Prospectively ECG gated CT pulmonary angiography versus helical un gated CT pulmonary angiography: impact on cardiac related motion artifacts and patient radiation dose. *Eur J Radiol* 2012;81(9):2444-9.

77. Dong C, Zhou M, Liu D, Long X, Guo T, Kong X. Diagnostic accuracy of computed tomography for chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. *PLoS One* 2015;10(4):e0126985.

78. Dournes G, Verdier D, Montaudon M, Bullier E, Rivière A, Dromer C, et al. Dual-energy CT perfusion and angiography in chronic thromboembolic pulmonary hypertension: diagnostic accuracy and concordance with radionuclide scintigraphy. *Eur Radiol* 2014;24(1):42-51.

79. He J, Fang W, Lv B, He JG, Xiong CM, Liu ZH, et al. Diagnosis of chronic thromboembolic pulmonary hypertension: comparison of ventilation/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography. *Nucl Med Commun* 2012;33(5):459-63.
80. Vonk Noordegraaf A, Haddad F, Bogaard HJ, Hassoun PM. Noninvasive imaging in the assessment of the cardiopulmonary vascular unit. *Circulation* 2015;131(10):899-913.
81. Saba TS, Foster J, Cockburn M, Cowan M, Peacock AJ. Ventricular mass index using magnetic resonance imaging accurately estimates pulmonary artery pressure. *Eur Respir J* 2002;20(6):1519-24.
82. van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG, Spreeuwenberg MD, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. *Eur Heart J* 2007;28(10):1250-7.
83. Yamada Y, Okuda S, Kataoka M, Tanimoto A, Tamura Y, Abe T, et al. Prognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapy. *Circ J* 2012;76(7):1737-43.
84. Ley S, Fink C, Zaporozhan J, Borst MM, Meyer FJ, Puderbach M, et al. Value of high spatial and high temporal resolution magnetic resonance angiography for differentiation between idiopathic and thromboembolic pulmonary hypertension: initial results. *Eur Radiol* 2005;15(11):2256-63.
85. Ohira H, Beanlands RS, Davies RA, Mielenzuk L. The role of nuclear imaging in pulmonary hypertension. *J Nucl Cardiol* 2015;22(1):141-57.
86. van de Veerdonk MC, Marcus JT, Bogaard HJ, Vonk Noordegraaf A. State of the art: advanced imaging of the right ventricle and pulmonary circulation in humans (2013 Grover Conference series). *Pulm Circ* 2014;4(2):158-68.
87. Connors AF Jr, Speroff T, Dawson NV, Thomas C, Harrell FE Jr, Wagner D, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. *JAMA* 1996;276(11):889-97.
88. Hadian M, Pinsky MR. Evidence-based review of the use of the pulmonary artery catheter: impact data and complications. *Crit Care* 2006;10 Suppl 3:S8.
89. Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. *Lancet* 2005;366(9484):472-7.
90. Richard C, Warszawski J, Anguel N, Deye N, Combes A, Barnoud D, et al. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 2003;290(20):2713-20.
91. Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, Doig CJ, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. *N Engl J Med* 2003;348(1):5-14.
92. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D, Wiedemann HP, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. *N Engl J Med* 2006;354(21):2213-24.
93. Rajaram SS, Desai NK, Kalra A, Gajera M, Cavanaugh SK, Brampton W, et al. Pulmonary artery catheters for adult patients in intensive care. *Cochrane Database Syst Rev* 2013 28;(2):CD003408.
94. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al.. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. *J Am Coll Cardiol* 2006;48(12):2546-52.
95. Mielenzuk LM, Chandy G, Stewart D, Contreras-Dominguez V, Haddad H, Pugliese C, et al. Worsening renal function and prognosis in pulmonary hypertension patients hospitalized for right heart failure. *Congest Heart Fail* 2012;18(3):151-7.
96. Bay M, Kir K, Parner J, Hassager C, Nielsen H, Krogsgaard K, et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. *Heart* 2003;89(2):150-4.
97. Blyth KG, Groenning BA, Mark PB, Martin TN, Foster JE, Steedman T, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. *Eur Respir J* 2007;29(4):737-44.
98. Cavagna L, Caporali R, Klersy C, Ghio S, Albertini R, Scelsi L, et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in
patients with systemic sclerosis. *J Rheumatol* 2010;37(10):2064-70.

99. Gan CT, McCann GP, Marcus JT, van Wolferen SA, Twisk JW, Boonstra A, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. *Eur Respir J* 2006;28(6):1190-4.

100. Souza R, Jardim C, Julio Cesar Fernandes C, Silveira Lapa M, Rabelo R, Humbert M. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. *Respir Med* 2007;101(1):69-75.

101. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyn P, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. *Chest* 2006;129(5):1313-21.

102. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *J Cardiol* 2001;37(2):110-1.

103. Qi a J, Wang Y, Huang C, Yang X, Zhao J, Wang Q, et al. Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis. *Autoimmun Rev* 2016;15(3):250-7.

104. Ali-Naamani N, Palevsky HI, Lederer DJ, Horn EM, Mathai SC, Roberts KE, et al. Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension. *Ann Am Thorac Soc* 2016;13(1):25-30.

105. Ventetuelo CE, Klinger JR. Management of acute right ventricular failure in the intensive care unit. *Ann Am Thorac Soc* 2014;11(5):811-22.

106. Mercat A, Diehl JL, Meyer G, Teboul JL, Sors H. Hemodynamic effects of fluid loading in acute massive pulmonary embolism. *Crit Care Med* 1999;27(3):540-4.

107. Jentzer JC, Mathier MA. Pulmonary Hypertension in the Intensive Care Unit. *J Intensive Care Med* 2016;31(6):369-85.

108. Piazza G, Goldhaber SZ. The acutely decompensated right ventricle: pathways for diagnosis and management. *Chest* 2005;128(3):1836-52.

109. Coz Yataco A, Aguinaga Meza M, Buch KP, Disselkamp MA. Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure. *Heart Fail Rev* 2016;21(3):323-46.

110. Boyd JH, Sirounis D. Assessment of adequacy of volume resuscitation. *Curr Opin Crit Care* 2016;22(5):424-7.

111. Préau S, Saulnier F, Dewavrin F, Durocher A, Chagnon JL. Passive leg raising is predictive of fluid responsiveness in spontaneously breathing patients with severe sepsis or acute pancreatitis. *Crit Care Med* 2010;38(3):819-25.

112. Ohashi M, Sato K, Suzuki S, Kinoshita M, Miyagawa K, Kojima M, et al. Doppler echocardiographic evaluation of latent pulmonary hypertension by passive leg raising. *Coron Artery Dis* 1997;8(10):651-5.

113. Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parfitt L, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. *Am J Respir Crit Care Med* 2014 (2):208-17.

114. Boechl L, Tamm M, Grendelmeier P, Stolz D. Acute effects of aerosolized iloprost in COPD related pulmonary hypertension - a randomized controlled crossover trial. *PLoS One* 2012;7(12):e52248.

115. De Wet CJ, Affleck DG, Jacobsohn E, Avidan MS, Tymkew H, Hill LL, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. *J Thorac Cardiovasc Surg* 2004;127(4):1058-67.

116. Khan TA, Schnickel G, Ross D, Bastani S, Laks H, Esmailian F, et al. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. *J Thorac Cardiovasc Surg* 2009;138(6):1417-24.

117. Bergot E, Sitbon O, Cottin V, Prévot G, Canuet M, Bourdin A, d et al. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. *Int J Cardiol* 2014 172(3):561-7.

118. Rubenfire M, McLaughlin VV, Allen RP, Elliott G, Park MH, Wade M, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. *Chest* 2007;132(3):757-63.
119. Humbert M, Sanchez O, Fartoukh M, Jagot JL, Le Gall C, Sitbon O, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. *Eur Respir J* 1999;13(6):1351-6.

120. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. *J Cardiovasc Pharmacol* 2003;41(2):293-9.

121. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. *Ann Intern Med* 1990;112(7):485-91.

122. Steffen RP, de la Mata M. The effects of I5AU8I, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensin systems of anesthetized dogs [corrected]. *Prostaglandins Leukot Essent Fatty Acids* 1991;43(4):277-86.

123. Alkukhun L, Bair ND, Dweik RA, Tonelli AR. Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertension. *J Cardiovasc Pharmacol* 2014;63(1):4-8.

124. Bauer SR, Tonelli AR. Beyond the evidence: treating pulmonary hypertension in the intensive care unit. *Crit Care* 2014;18(5):524.

125. Haraldsson A, Kieler-Jensen N, Nathorst-Westfelt U, Bergh CH, Ricksten SE. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. *Chest* 1998;114(3):780-6.

126. Schroeder RA, Wood GL, Plotkin JS, Kuo PC. Intraoperative use of inhaled PGI(2) for acute pulmonary hypertension and right ventricular failure. *Anesth Analg* 2000;91(2):291-5.

127. Seyfarth HJ, Gille J, Sablotzki A, Gerlach S, Malcharek M, Gosse A, et al. Perioperative management of patients with severe pulmonary hypertension in major orthopedic surgery: experience-based recommendations. *GMS Interdiscip Plast Reconstr Surg DGPW* 2015;4:Doc03.

128. Reddy MT, Patel H, Ventura HO. Successful transition from intravenous to inhaled prostacyclin in a patient with pulmonary hypertension and right ventricular failure. *Congest Heart Fail* 2008;14(5):285-6.

129. Haraldsson A, Kieler-Jensen N, Ricksten SE. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. *J Cardiothorac Vasc Anesth* 1996;10(7):864-8.

130. van Heerden PV, Barden A, Michalopoulos N, Bulsara MK, Roberts BL. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. *Chest* 2000;117(3):819-27.

131. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapon V, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. *J Am Coll Cardiol* 2010;55(18):1915-22.

132. Voswinckel R, Reichenberger F, Enke B, Kreckel A, Krick S, Gall H, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. *Pulm Pharmacol Ther* 2008;21(5):824-32.

133. Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. *J Am Coll Cardiol* 2006;48(8):1672-81.

134. Voswinckel R, Reichenberger F, Gall H, Schmehl T, Gessler T, Schermuly RT, et al. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. *Pulm Pharmacol Ther* 2009;22(1):50-6.

135. Parikh KS, Rajagopal S, Fortin T, Tapon VF, Poms AD. Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension. *J Cardiovasc Pharmacol* 2016;67(4):322-5.

136. Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapon VF, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. *J Heart Lung Transplant* 2011;30(12):1327-33.

137. Zamanian RT, Levine DJ, Bourge RC, De Souza SA, Rosenzweig EB, Alnuaimat H, et al. An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension. *Pulm Circ* 2016;6(3):329-37.
138. de Jesus Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, et al. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. *Am J Cardiol* 2012;110(10):1546-50.

139. Krug S, Hammerschmidt S, Pankau H, Wirtz H, Seyfarth HJ. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension. *Respiration* 2008;76(2):154-9.

140. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. *N Engl J Med* 2002;347(5):322-9.

141. Rex S, Schaefter G, Metzelder S, Flier S, de Waal EE, Autschbach R, et al. Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial. *Acta Anaesthesiol Scand* 2008;52(1):65-72.

142. Theodoraki K, Rellia P, Thanopoulos A, Tsourelis L, Zarkalis D, Sfyrikis P, Antoniou T. Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass. *Can J Anaesth* 2002;49(9):963-7.

143. Scott LJ. Selexipag: First Global Approval. *Drugs* 2016;76(3):413-8.

144. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karłocai K, Galiè N, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. *Eur Respir J* 2012;40(4):874-80.

145. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. *N Engl J Med* 2015;373(26):2522-33.

146. Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. *Crit Care Med* 1998;26(1):15-23.

147. Wennmalm A, Benthin G, Edlund A, Jungersten L, Kiel Jensen N, Lundin S, et al. Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. *Circ Res* 1993;73(6):1121-7.

148. Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. *Cochrane Database Syst Rev* 2016;(6):CD002787.

149. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. *N Engl J Med* 1996;334(5):296-301.

150. Badesch DB, Bodin F, Channick RN, Frost A, Rainisio M, Robbins IM, et al. Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. *Current therapeutic research* 2002;63(4):227-46.

151. McGinn K, Reichert M. A Comparison of Inhaled Nitric Oxide Versus Inhaled Epoprostenol for Acute Pulmonary Hypertension Following Cardiac Surgery. *Ann Pharmacother* 2016;50(1):22-6.

152. Kholdani CA, Fares WH. Management of Right Heart Failure in the Intensive Care Unit. *Clin Chest Med* 2015;36(3):511-20.

153. Christenson J, Lavoie A, O’Connor M, Bhorade S, Pohlman A, Hall JB. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. *Am J Respir Crit Care Med* 2000;161(5):1443-9.

154. Wharton J, Strange JW, Møller GM, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. *Am J Respir Crit Care Med* 2005;172(1):105-13.

155. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. *Lancet* 2002;360(9337):895-900.

156. Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadaš B, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. *J Am Coll Cardiol* 2004;44(7):1488-96.

157. Lee JE, Hillier SC, Knoderer CA. Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. *J Intensive Care Med* 2008;23(5):329-34.
158. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. *Am J Respir Crit Care Med* 2006;174(9):1042-7.

159. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. *Anesthesiology* 1999;91(1):307-10.

160. Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. *Chest* 2005;127(5):1647-53.

161. Bigatello LM, Hess D, Dennehy KC, Medoff BD, Hurford WE. Sildenafil can increase the response to inhaled nitric oxide. *Anesthesiology* 2000;92(6):1827-9.

162. Matamis D, Pampori S, Papathanasiou A, Papakonstantinou P, Tsagourias M, Galiatsou E, et al. Inhaled NO and sildenafil combination in cardiac surgery patients with out-of-proportion pulmonary hypertension: acute effects on postoperative gas exchange and hemodynamics. *Circ Heart Fail* 2012;5(1):47-53.

163. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. *Ann Intern Med* 2008;149(8):521-30.

164. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weismann N, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. *Ann Intern Med* 2002;136(7):515-22.

165. Wilkens H, Guth A, König J, Forester N, Cremers B, Hennen B, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. *Circulation* 2001;104(11):1218-22.

166. Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. *Eur J Clin Investig* 2006;36 Suppl 3:32-8.

167. Gruenig E, Michelakis E, Vachiéry JL, Vizza CD, Meyer FJ, Doebber M, et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-I study. *J Clin Pharmacol* 2009;49(11):1343-52.

168. Hatano M, Yao A, Kinugawa K, Hirata Y, Nagai R. Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan. *Int Heart J* 2011;52(4):233-9.

169. Dardi F, Manes A, Palazzini M, Bachetti C, Mazzanti G, Rinaldi A, et al. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. *Eur Respir J* 2015;46(2):414-21.

170. Vachiéry JL, Huez S, Gillies H, Layton G, Hayashi N, Gao X, et al. Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. *Br J Clin Pharmacol* 2011;71(2):289-92.

171. Mikhail GW, Prasad SK, Li W, Rogers P, Chester AH, Bayne S, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. *Eur Heart J* 2004;25(5):431-6.

172. Suntharalingam J, Hughes RJ, Goldsmith K, Doughty N, George P, Toshner M, et al. Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). *Vascul Pharmacol* 2007;46(6):449-55.

173. Montalescot G, Drobinski G, Meurin P, Maclouf J, Sotirov I, Philippe F, et al. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. *Am J Cardiol* 1998;82(6):749-55.

174. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. *N Engl J Med* 1986;314(6):349-58.

175. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. *J Clin Invest* 1985;75(2):643-9.

176. Chen EP, Bittner HB, Davis RD Jr, Van Trigt P 3rd. Milrinone improves pulmonary hemodynamics and right ventricular
function in chronic pulmonary hypertension. *Ann Thorac Surg* 1997;63(3):814-21.

177.Zheng J, Ma J, Zhang P, Hu L, Fan X, Tang Q. Milrinone inhibits hypoxia or hydrogen dioxide-induced persistent sodium current in ventricular myocytes. *Eur J Pharmacol* 2009;616(1-3):206-12.

178.Kato R, Sato J, Nishino T. Milrinone decreases both pulmonary arterial and venous resistances in the hypoxic dog. *Br J Anaesth* 1998;81(6):920-4.

179.Lee JH, Oh YJ, Shim YH, Hong YW, Yi G, Kwak YL. The effect of milrinone on the right ventricular function in patients with reduced right ventricular function undergoing off-pump coronary artery bypass graft surgery. *J Korean Med Sci* 2006;21(5):854-8.

180.Baruch L, Patacsil P, Hameed A, Pina I, Loh E. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. *Am Heart J* 2001;141(2):266-73.

181.McNamara PJ, Laique F, Muang-In S, Whyte HE. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. *J Crit Care* 2006;21(2):217-22.

182.Cai J, Su Z, Shi Z, Zhou Y, Xu Z, Xu Z, et al. Nitric oxide and milrinone: combined effect on pulmonary circulation after Fontan-type procedure: a prospective, randomized study. *Ann Thorac Surg* 2008;86(3):882-8; discussion 882-8.

183.Sablotzki A, Starzmann W, Scheubel R, Grond S, Czeslick EG. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. *Can J Anaesth* 2005;52(10):1076-82.

184.Wang H, Gong M, Zhou B, Dai A. Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. *Adv Ther* 2009;26(4):462-8.

185.Denault AY, Bussières JS, Arellano R, Finegan B, Gavra P, Haddad F, et al. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. *Can J Anaesth* 2016;63(10):1140-53.

186.Haraldsson s A, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. *Anesth Analg* 2001;93(6):1439-45.

187.Thelitz S, Oishi P, Sanchez LS, Bekker JM, Ovadia B, Johengen MJ, et al. Phosphodiesterase-3 inhibition prevents the increase in pulmonary vascular resistance following inhaled nitric oxide withdrawal in lambs. *Pediatr Crit Care Med* 2004;5(3):234-9.

188.De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al. Comparison of dopamine and norepinephrine in the treatment of shock. *N Engl J Med* 2010;362(9):779-89.

189.Kurzyna M, Zyllkowska J, Fijalkowsa A, Florczyk M, Wieteska M, Kacprzak A, et al. Characteristics and prognosis of patients with decompensated right ventricular failure during the course of pulmonary hypertension. *Kardiol Pol* 2008;66(10):1033-9; discussion 1040-1.

190.Acosta F, Sansano T, Palenciano CG, Falcon L, Domenech P, Robles R, et al. Effects of dobutamine on right ventricular function and pulmonary circulation in pulmonary hypertension during liver transplantation. *Transplant Proc* 2005;37(9):3869-70.

191.Ferrario M, Poli A, Previtali M, Lanzarini L, Fetteiveau R, Dietallevi P, et al. Hemodynamics of volume loading compared with dobutamine in severe right ventricular infarction. *Am J Cardiol* 1994;74(4):329-33.

192.Andersen MJ, Hwang SJ, Kane GC, Melenovsky V, Olson TP, Fetterly K, et al. Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction. *Circ Heart Fail* 2015;8(3):542-50.

193.Akagi S, Ogawa A, Miyaji K, Kusano K, Ito H, Matsubara H. Catecholamine support at the initiation of epoprostenol therapy in pulmonary arterial hypertension. *Ann Am Thorac Soc* 2014;11(5):719-27.

194.Vizza CD, Rocca GD, Roma AD, Iacoboni C, Pierconti F, Venuta F, et al. Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. *Crit Care* 2001;5(6):355-61.
195. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. *Circulation* 2005;111(12):1504-9.

196. Oldner A, Konrad D, Weitzberg E, Rudehill A, Rossi P, Wanecek M. Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. *Crit Care Med* 2001;29(11):2185-93.

197. Kerbaul F, Gariboldi V, Giorgi R, Mekkaoui C, Guieu R, Fesler P, et al. Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure. *Crit Care Med* 2007;35(8):1948-54.

198. Vildbrad MD, Andersen A, Holmboe S, Ringgaard S, Nielsen JM, Nielsen-Kudsk JE. Acute effects of levosimendan in experimental models of right ventricular hypertrophy and failure. *Pulm Circ* 2014;4(3):511-9.

199. Tavares-Silva M, Alaa M, Leite S, Oliveira-Pinto J, Lopes L, Leite-Moreira AF, et al. Dose-Response Head-to-Head Comparison of Inodilators Dobutamine, Milrinone, and Levosimendan in Chronic Experimental Pulmonary Hypertension. *J Cardiovasc Pharmacol Ther* 2017;22(5):485-495.

200. Gandham R, Syamasundar A, Ravulapalli H, Karthekeyan RB, Vakamudi M, Kodalli R, et al. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair / replacement for severe mitral stenosis. *Ann Card Anaesth* 2013;16(1):11-5.

201. Mishra A, Kumar B, Dutta V, Arya VK, Mishra AK. Comparative Effect of Levosimendan and Milrinone in Cardiac Surgery Patients With Pulmonary Hypertension and Left Ventricular Dysfunction. *J Cardiothorac Vasc Anesth* 2016;30(3):639-46.

202. Pathak A, Lebrin M, Vaccaro A, Senard JM, Despas F. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects. *J Clin Pharm Ther* 2013;38(5):341-9.

203. Joynt C, Bigam DL, Charrois G, Jewell LD, Korbutt G, Cheung PY. Milrinone, dobutamine or epinephrine use in asphyxiated newborn pigs resuscitated with 100% oxygen. *Intensive Care Med* 2010;36(6):1058-66.

204. Meadow WL, Rudinsky BF, Strates E. Selective elevation of systemic blood pressure by epinephrine during sepsis-induced pulmonary hypertension in piglets. *Pediatr Res* 1986;20(9):872-5.

205. Cheung PY, Barrington KJ. The effects of dopamine and epinephrine on hemodynamics and oxygen metabolism in hypoxic anesthetized piglets. *Crit Care* 2001;5(3):158-66.

206. Siehr SL, Feinstein JA, Yang W, Peng LF, Ogawa MT, Ramamoorthy C. Hemodynamic Effects of Phenytolephrine, Vasopressin, and Epinephrine in Children With Pulmonary Hypertension: A Pilot Study. *Pediatr Crit Care Med* 2016;17(5):428-37.

207. Westfall TC, Macarthur H, Westfall DP. Adrenergic Agonists and Antagonists. In: Brunton LL, Knollmann BC, Hilal-Dandan R, editors. Goodman &amp; Gilman's: The Pharmacological Basis of Therapeutics, 13th ed. New York, NY: McGraw-Hill Education; 2017.

208. Martin C, Perrin G, Saux P, Papazian L, Gouin F. Effects of norepinephrine on right ventricular function in septic shock patients. *Intensive Care Med* 1994;20(6):444-7.

209. Kerbaul F, Rondelet B, Motte S, Fesler P, Hubloue I, Ewalenko P, et al. Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. *Crit Care Med* 2004;32(4):1035-40.

210. Angle MR, Molloy DW, Penner B, Jones D, Prewitt RM. The cardiopulmonary and renal hemodynamic effects of norepinephrine in canine pulmonary embolism. *Chest* 1991;100(3):796-801.

211. Bertolissi M, Bassi F, Da Broi U. Norepinephrine can be useful for the treatment of right ventricular failure combined with acute pulmonary hypertension and systemic hypotension. A case report. *Minerva Anestesiol* 2001;67(1-2):79-84.
214. Kwak YL, Lee CS, Park YH, Hong YW. The effect of phenylephrine and norepinephrine in patients with chronic pulmonary hypertension. *Anaesthesia* 2002;57(1):9-14.

215. Rich S, Gubin S, Hart K. The effects of phenylephrine on right ventricular performance in patients with pulmonary hypertension. *Chest* 1990;98(5):1102-6.

216. Curranigan DA, Hughes RJ, Wright CE, Angus JA, Soeding PF. Vasoconstrictor responses to vasopressor agents in human pulmonary and radial arteries: an in vitro study. *Anesthesiology* 2014;121(5):930-6.

217. Walker BR, Haynes J Jr, Wang HL, Voelkel NF. Vasopressin-induced pulmonary vasodilation in rats. *Am J Physiol* 1989;257(2 Pt 2):H415-22.

218. Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. *Chest* 1993;103(4):1241-5.

219. Dünser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. *Anesth Analg* 2001;93(1):7-13.

220. Jin HK, Chen YF, Yang RH, McKenna TM, Jackson RM, Oparil S. Vasopressin lowers pulmonary artery pressure in hypoxic rats by releasing atrial natriuretic peptide. *Am J Med Sci* 1989;298(4):227-36.

221. Katusic ZS, Shepherd JT, Vanhoutte PM. Vasopressin causes endothelium-dependent relaxations of the canine basilar artery. *Circ Res* 1984;55(5):575-9.

222. Mols P, Hallemans R, Van Kuyk M, Melot C, Lejeune P, Ham H, et al. Hemodynamic effects of vasopressin, alone and in combination with nitroprusside, in patients with liver cirrhosis and portal hypertension. *Ann Surg* 1984;199(2):176-81.

223. Leather HA, Segers P, Berends N, Vandermeersch E, Wouters PF. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. *Crit Care Med* 2002;30(11):2548-52.

224. Wang M, Shibamoto T, Kuda Y, Tanida M, Kurata Y. Systemic vasoconstriction modulates the responses of pulmonary vasculature and airway to vasoconstrictors in anesthetized rats. *Exp Lung Res* 2015;41(6):324-34.

225. Enomoto M, Pan J, Shifrin Y, Belik J. Age dependency of vasopressin pulmonary vasodilatory effect in rats. *Pediatr Res* 2014;75(2):315-21.

226. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med* 2008;358(9):877-87.

227. Gordon AC, Wang N, Walley KR, Ashby D, Russell JA. The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. *Chest* 2012;142(3):593-605.

228. Obrist MD, Jung R, Fish DN, MacLaren R. Effects of continuous vasopressin infusion in patients with septic shock. *Ann Pharmacother* 2004;38(7-8):1117-22.

229. Tayama E, Ueda T, Shojima T, Akasu K, Oda T, Fukunaga S, et al. Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. *Interact Cardiovasc Thorac Surg* 2007;6(6):715-9.

230. Price LC, Forrest P, Sodhi V, Adamson DL, Nelson-Piercy C, Lucey M, et al. Use of vasopressin after Caesarean section in idiopathic pulmonary arterial hypertension. *Br J Anaesth* 2007;99(4):552-5.

231. Scheuermann MA, Bradley SM, Atz AM. Vasopressin to attenuate pulmonary hypertension and improve systemic blood pressure after correction of obstructed total anomalous pulmonary venous return. *J Thorac Cardiovasc Surg* 2005;129(2):464-6.

232. Braun EB, Palin CA, Hogue CW. Vasopressin during spinal anesthesia in a patient with primary pulmonary hypertension treated with intravenous epoprostenol. *Anesth Analg* 2004;99(1):36-7.

233. Lahm T, McCaslin CA, Wozniak TC, Ghuman W, Fadl YY, Obeidat OS, et al. Medical and surgical treatment of acute right ventricular failure. *J Am Coll Cardiol* 2010;56(18):1435-46.

234. Price LC, Dimopoulos K, Marino P, Alonso-Gonzalez R, McCabe C, Kemnpy A, et al. The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. *Thorax* 2017;72(11):1035-1045.
235. Leuchte HH, Baezner CJ, Baumgartner RA, Mernitz P, Neurohr C, Behr J. Acute hemodynamic responses to supplemental oxygen and their prognostic implications in pulmonary hypertension. *Respiration* 2013;85(5):400-7.

236. Jardin F, Delorme G, Hardy A, Auvert B, Beauchet A, Bourdarias JP. Reevaluation of hemodynamic consequences of positive pressure ventilation: emphasis on cyclic right ventricular afterloading by mechanical lung inflation. *Anesthesiology* 1990;72(6):966-70.

237. Rush B, Biagioni BJ, Berger L, McDermid R. Mechanical Ventilation Outcomes in Patients With Pulmonary Hypertension in the United States: A National Retrospective Cohort Analysis. *J Intensive Care Med* 2017;32(10):588-592.

238. Viitanen A, Salmenperä M, Heinonen J. Right ventricular response to hypercarbia after cardiac surgery. *Anesthesiology* 1990;73(3):393-400.

239. Viitanen A, Salmenperä M, Heinonen J, Hynynen M. Pulmonary vascular resistance before and after cardiopulmonary bypass. The effect of PaCO2. *Chest* 1989;95(4):773-8.

240. Puybasset L, Stewart T, Roubey JJ, Cluzel P, Mourgeon E, Belin MF, et al. Inhaled nitric oxide reverses the increase in pulmonary vascular resistance induced by permissive hypercapnia in patients with acute respiratory distress syndrome. *Anesthesiology* 1994;80(6):1254-67.

241. Kantores C, McNamara PJ, Teixeira L, Engelberts D, Murthy P, Kavanagh BP, et al. Therapeutic hypercapnia prevents chronic hypoxia-induced pulmonary hypertension in the newborn rat. *Am J Physiol Lung Cell Mol Physiol* 2006;291(5):L1912-22.

242. Ooi H, Cadogan E, Sweeney M, Howell K, O’Regan RG, McLoughlin P. Chronic hypercapnia inhibits hypoxic pulmonary vascular remodeling. *Am J Physiol Heart Circ Physiol* 2000;278(2):H331-8.

243. Repessé X, Vieillard-Baron A. Hypercapnia during acute respiratory distress syndrome: the tree that hides the forest! *J Thorac Dis* 2017;9(6):1420-1425.

244. Zhong HJ, Wang W, Zhao B, Yang TD. Permissive hypercapnia combined with low-level PEEP in bullous emphysema patient undergoing cardiac surgery: a case report and literature review. *Int J Clin Exp Med* 2016;9(2):4680-4.

245. Zamanian RT, Kudelko KT, Sung YK, Perez VJ, Liu J, Spiekeroetter E. Current clinical management of pulmonary arterial hypertension. *Circ Res* 2014;115(1):131-147.

246. Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000;342(18):1301-8.

247. Needham DM, Colantuoni E, Mendez-Tellez PA, Dinglas VD, Sevrlanske JE, Dennison Himmelfarb CR, et al. Lung protective mechanical ventilation and two year survival in patients with acute lung injury: prospective cohort study. *BMJ* 2012;344:e2124.

248. Amato MB, Meade MO, Slutsky AS, Brochard L, Costa EL, Schoenfeld DA, et al. Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med* 2015;372(8):747-55.

249. Chiu LC, Hu HC, Hung CY, Chang CH, Tsai FC, Yang CT, et al. Dynamic driving pressure associated mortality in acute respiratory distress syndrome with extracorporeal membrane oxygenation. *Ann Intensive Care* 2017;7(1):12.

250. Gattinoni L, Caironi P, Cressoni M, Chiumello D, Ranieri VM, Quintel M, et al. Lung recruitment in patients with the acute respiratory distress syndrome. *N Engl J Med* 2006;354(17):1775-86.

251. Camporota L, Barrett N. Current Applications for the Use of Extracorporeal Carbon Dioxide Removal in Critically Ill Patients. *Biomed Res Int* 2016;2016:9781695.

252. Abrams D, Brodie D. Novel Uses of Extracorporeal Membrane Oxygenation in Adults. *Clin Chest Med* 2015;36(3):373-84.

253. Pereszlenyi A, Lang G, Steltzer H, Hetz H, Kocher A, Neuhauser P, et al. Bilateral lung transplantation with intra- and postoperatively prolonged ECMO support in patients with pulmonary hypertension. *Eur J Cardiothorac Surg* 2002;21(5):858-63.

254. Salman J, Ius F, Sommer W, Siemeni T, Kuehn C, Avsar M, et al. Mid-term results of bilateral lung transplant with postoperatively extended intraoperative extracorporeal
membrane oxygenation for severe pulmonary hypertension. *Eur J Cardiothorac Surg* 2017;52(1):163-170.

255.Keogh AM, Mayer E, Benza RL, Corris P, Dartevelle PG, Frost AE, et al. Interventional and surgical modalities of treatment in pulmonary hypertension. *J Am Coll Cardiol* 2009;54(1 Suppl):S67-77.

256.Punnoose L, Burkhoff D, Rich S, Horn EM. Right ventricular assist device in end-stage pulmonary arterial hypertension: insights from a computational model of the cardiovascular system. *Prog Cardiovasc Dis* 2012;55(2):234-243.e2.

257.Welp H, Sindermann JR, Deschka H, Martens S, Scherer M. Pulmonary Bleeding During Right Ventricular Support After Left Ventricular Assist Device Implantation. *J Cardiothorac Vasc Anesth* 2016;30(3):627-31.

258.Deschka H, Holthaus AJ, Sindermann JR, Welp H, Schlarb D, Monsefi N, et al. Can Perioperative Right Ventricular Support Prevent Postoperative Right Heart Failure in Patients With Biventricular Dysfunction Undergoing Left Ventricular Assist Device Implantation? *J Cardiothorac Vasc Anesth* 2016;30(3):619-26.

259.Haneya A, Philipp A, Puehler T, Ruppecht L, Kobuch R, Hilker M, et al. Temporary percutaneous right ventricular support using a centrifugal pump in patients with postoperative acute refractory right ventricular failure after left ventricular assist device implantation. *Eur J Cardiothorac Surg* 2012;41(1):219-23.

260.Kormos RL, Teuteberg JJ, Pagani FD, Russell SD, John R, Miller LW, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. *J Thorac Cardiovasc Surg* 2010;139(5):1316-24.

261.Leidenfrost J, Prasad S, Itok A, Lawrance CP, Bell JM, Silvestry SC. Right ventricular assist device with membrane oxygenator support for right ventricular failure following implantable left ventricular assist device placement. *Eur J Cardiothorac Surg* 2016;49(1):73-7.

262.Ochiai Y, McCarthy PM, Smedira NG, Banbury MK, Navia JL, Feng J, et al. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. *Circulation* 2002;106(12 Suppl 1):I198-202.

263.Atiemo AD, Conte JV, Heldman AW. Resuscitation and recovery from acute right ventricular failure using a percutaneous right ventricular assist device. *Catheter Cardiovasc Interv* 2006;68(1):78-82.

264.Giesler GM, Gomez JS, Letsou G, Vooleitch M, Smalling RW. Initial report of percutaneous right ventricular assist for right ventricular shock secondary to right ventricular infarction. *Catheter Cardiovasc Interv* 2006;68(2):263-6.

265.Hangler HB, Bonatti JO, Antretter H, Mair P, Müller LC. Isolated right ventricular assist for postcardiotomy myocardial infarction. *Ann Thorac Surg* 1999;68(6):2326-8.

266.Kapur NK, Paruchuri V, Korabathina R, Al-Mohammdi R, Mudd JO, Prutkin J, et al. Effects of a percutaneous mechanical circulatory support device for medically refractory right ventricular failure. *J Heart Lung Transplant* 2011;30(12):1360-7.

267.Klima U, Ringes-Lichtenberg S, Warnecke G, Lichtenberg A, Strüber M, Haverich A. Severe right heart failure after heart transplantation. A single-center experience. *Transpl Int* 2005;18(3):326-32.

268.Moazami N, Pasque MK, Moon MR, Herren RL, Bailey MS, Lawton JS, et al. Mechanical support for isolated right ventricular failure in patients after cardiotomy. *J Heart Lung Transplant* 2004;23(12):1371-5.

269.Anderson MB, Goldstein J, Milano C, Morris LD, Kormos RL, Bham J, et al. Benefits of a novel percutaneous ventricular assist device for right heart failure: The prospective RECOVER RIGHT study of the Impella RP device. *J Heart Lung Transplant* 2015;34(12):1549-60.

270.Fonger JD, Borkon AM, Baumgartner WA, Achuff SC, Augustine S, Reitz BA. Acute right ventricular failure following heart transplantation: improvement with prostaglandin E1 and right ventricular assist. *J Heart Transplant* 1986;5(4):317-21.

271.Gregoric ID, Chandra D, Myers TJ, Scheinin SA, Loyalka P, Kar B. Extracorporeal membrane oxygenation as a bridge to emergency heart-lung transplantation in a patient with idiopathic pulmonary arterial hypertension. *J Heart Lung Transplant* 2008;27(4):466-8.
272. Hansen LN, Berg H, Schmidt H, Veien KT, Jensen MK, Junker A, et al. Percutaneous right ventricular assist device in sepsis due to right ventricular failure and pulmonary hypertension. *Acta Anaesthesiol Scand* 2016;60(10):1470-1472.

273. Nagarsheth NP, Pinney S, Bassily-Marcus A, Anyanwu A, Friedman L, Beilin Y. Successful placement of a right ventricular assist device for treatment of a presumed amniotic fluid embolism. *Anesth Analg* 2008;107(3):962-4.

274. Rosenzweig EB, Chicotka S, Bacchetta M. Right ventricular assist device use in ventricular failure due to pulmonary arterial hypertension: Lessons learned. *J Heart Lung Transplant* 2016;35(10):1272-1274.

275. Goldstein JA, Kern MJ. Percutaneous mechanical support for the failing right heart. *Cardiol Clin* 2012;30(2):303-10.

276. Camboni D, Philipp A, Arlt M, Pfeiffer M, Hilker M, Schmid C. First experience with a paracorporeal artificial lung in humans. *ASAIO J* 2009;55(3):304-6.

277. Schmid C, Philipp A, Hilker M, Arlt M, Trabold B, Pfeiffer M, et al. Bridge to lung transplantation through a pulmonary artery to left atrial oxygenator circuit. *Ann Thorac Surg* 2008;85(4):1202-5.

278. Strueber M, Hoeper MM, Fischer S, Cypel M, Warnecke G, Gottlieb J, et al. Bridge to thoracic organ transplantation in patients with pulmonary arterial hypertension using a pumpless lung assist device. *Am J Transplant* 2009;9(4):853-7.

279. Vasanthan V, Garg M, Maruyama M, Michelakis E, Freed DH, Nagendran J. Extended Bridge to Heart and Lung Transplantation Using Pumpless Extracorporeal Lung Assist. *Can J Cardiol* 2017;33(7):950.e11-950.e13.

280. Chiu JS, Zuckerman WA, Turner ME, Richmond ME, Kerstein D, Krishnan U, et al. Balloon atrial septostomy in pulmonary arterial hypertension: effect on survival and associated outcomes. *J Heart Lung Transplant* 2015;34(3):376-80.

281. Rothman A, Sklansky MS, Lucas VW, Kashani IA, Shaughnessy RD, Channick RN, et al. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. *Am J Cardiol* 1999;84(6):682-6.

282. Stümpfer O, Gewillig M, Vettukattil J, Budts W, Chessa M, Chaudhari M, et al. Modified technique of stent fenestration of the atrial septum. *Heart* 2003;89(10):1227-30.

283. Trost JC, Hillis LD. Intra-aortic balloon counterpulsation. *Am J Cardiol* 2006;97(9):1391-8.

284. De Silva K, Lumley M, Kailey B, Alastruey J, Guilcher A, Asrress KN, et al. Coronary and microvascular physiology during intra-aortic balloon counterpulsation. *JACC Cardiovasc Inter* 2014;7(6):631-40.

285. Darrah WC, Sharpe MD, Guiraudon GM, Neal A. Intraaortic balloon counterpulsation improves right ventricular failure resulting from pressure overload. *Ann Thorac Surg* 1997;64(6):1718-23; discussion 1723-4.

286. Vanden Eynden F, Mets G, De Somer F, Bouchez S, Bove T. Is there a place for intra-aortic balloon counterpulsation support in acute right ventricular failure by pressure-overload? *Int J Cardiol* 2015;197:227-34.

287. Liakopoulos OJ, Ho JK, Yezbick AB, Sanchez E, Singh V, Mahajan A. Right ventricular failure resulting from pressure overload: role of intra-aortic balloon counterpulsation and vasopressor therapy. *J Surg Res* 2010;164(1):58-66.

288. Gold JP, Shemin RJ, DiSesa VJ, Cohn L, Collins JJ Jr. Balloon pump support of the failing right heart. *Clin Cardiol* 1985;8(11):599-602.

289. Kopman EA, Ramirez-Inawat RC. Intra-aortic balloon counterpulsation for right heart failure. *Anesth Analg* 1980,59(1):74-6.

290. Arafa OE, Geiran OR, Andersen K, Fosse E, Simonsen S, Svennevig JL. Intraaortic balloon pumping for predominantly right ventricular failure after heart transplantation. *Ann Thorac Surg* 2000;70(5):1587-93.

291. Boeken U, Feindt P, Litmathe J, Kurt M, Gams E. Intraaortic balloon pumping in patients with right ventricular insufficiency after cardiac surgery: parameters to predict failure of IABP Support. *Thorac Cardiovasc Surg* 2009;57(6):324-8.